

PSI is a leading full-service CRO operating globally. 98% of PSI-managed clinical trials complete patient enrollment on or ahead of schedule.

PSI's exceptional repeat and referral business rate distinguishes PSI in the market place as a "no-nonsense" CRO that delivers across trials of all sizes and levels of complexity.

PSI has successfully performed Phase II/III studies in the following cancer indications:



- Breast
- NSCLC
- SCLC
- Gastric
- Pancreatic
- Ovarian
- Cervical
- Prostate
- Renal
- Melanoma
- Head & Neck
- Bladder
- Esophageal
- Colorectal
- Kaposi's sarcoma
- Leukemias
- Bone metastases
- Chemotherapy-induced nausea and vomiting
- Chemotherapy-induced neutropenia
- Hepatic
- Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
- Multiple Myeloma
- Hematologic Cancers*

** please refer to Hematology Fact Sheet*

PSI has experience with the following types of cancer therapeutics:

- Alkylating agents
- Antimetabolites
- Anthracyclines
- Taxanes
- Platinum agents
- Antiestrogens
- Aromatase inhibitors
- Vinca derivatives
- Podophylotoxin derivatives
- Interleukins
- Agents influencing apoptosis
- Angiogenesis inhibitors
- Retinoids
- Radiosensitizers
- Growth factors
- Antibodies
- Vaccines
- Biphosphonates
- Antiemetics
- Taxane enhancers
- Toxicity modulators

PSI has worked with liposomal, micellar and nanoparticle formulations.

PSI has managed Phase I, II and III cancer studies.

PSI has run studies in neoadjuvant, adjuvant and advanced disease settings.

PSI employs physicians as full-time monitors and project managers, most of whom are board certified specialists, including medical oncologists.

ULTRA-FAST PATIENT ENROLLMENT. IT'S ABOUT TIME.

For more information,
please contact us:

WWW.PSI-CRO.COM

Ginny Payeur

Phone: +1 650 592 9101

E-mail: Ginny.Payeur@psi-cro.com

Iain Gordon

Phone: +44 7738 006 738

E-mail: Iain.Gordon@psi-cro.com